Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

ER, HER2, and TOP2A expression in primary tumor, synchronous axillary nodes, and asynchronous metastases in breast cancer

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Risk of breast cancer among women with benign ovarian tumors: a Danish nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sentinel and non-sentinel lymph node metastases in patients with microinvasive breast cancer: a nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Screening mammography: benefit of double reading by breast density

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Mortality after contralateral breast cancer in Denmark

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Is DBCG abreast of new developments?

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007-2016

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Application of automated image analysis reduces the workload of manual screening of sentinel lymph node biopsies in breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
At recurrence of breast cancer, the therapeutic target is the metastases. However, it is current practice to base the choice of systemic treatment on the biomarker profile of the primary tumor. In the present study, confirmatory biopsies were obtained from suspected metastatic lesions and compared with the primary tumors with respect to ER, HER2, and TOP2A. In the prospective tissue-collection study, 81 patients had biopsy from a suspected relapse. Additional archived paired material was included, leaving a total of 119 patients with paired primary tumor, synchronous axillary nodes (available in 52 patients) and asyncronous metastases available for analysis. ER, HER2, and TOP2A expression of primary tumors, axillary nodes and metastases were re-analysed and determined centrally by immunohistochemistry, chromogenic in situ hybridization, and fluorescence in situ hybridization. Of the 81 patients with a biopsy from a suspected relapse, 65 (80%) were diagnosed with recurrent breast carcinoma, 3 (4%) were diagnosed with other malignancies, 6 (7%) had benign conditions, and in 7 (9%) patients the biopsy was non-representative. Discordance in ER, HER2, and TOP2A (aberration vs. normal) status between primary tumor and corresponding asynchronous metastasis was 12% (14/118), 9% (10/114), and 23% (17/75), respectively. There were no significant associations with biomarker discordance and prior adjuvant therapy, or location of biopsy. Expression of ER, HER2, and TOP2A displayed discordance with a sufficient frequency to emphasize the role of confirmatory biopsies from metastatic lesions in future management of recurrent breast cancer.
OriginalsprogEngelsk
TidsskriftBreast Cancer Research and Treatment
Vol/bind132
Udgave nummer2
Sider (fra-til)511-521
ISSN0167-6806
DOI
StatusUdgivet - 2012

ID: 33230893